Answers are grounded in this paper and cite their sources.
Background: New-onset refractory status epilepticus (NORSE) is a severe form of status epilepticus occurring without preexisting epilepsy or identifiable acute structural, toxic, or metabolic cause within 72 hours. Febrile infection-related epilepsy syndrome (FIRES) is a subtype preceded by a febrile illness 2 weeks to 24 hours before onset. A substantial proportion of cases remain cryptogenic, posing major diagnostic and therapeutic challenges. Objectives: To characterize the clinical profile and treatment outcomes of NORSE and FIRES, compare cryptogenic NORSE with FIRES, and identify correlations between treatment modalities, disease parameters, and functional outcomes. Methods: A single-center prospective study was conducted at a tertiary care hospital. Twenty patients presenting with refractory (RSE) or super-refractory status epilepticus (SRSE) were enrolled after excluding acute structural, toxic, or metabolic causes. Patients were classified into known and unknown etiology groups. Demographics, seizure type, time to first antiseizure medication (ASM), electroencephalography, magnetic resonance imaging (MRI), cerebrospinal fluid autoimmune and paraneoplastic antibody panels, immunotherapy details, and functional outcomes (Glasgow Outcome Scale, GOS) at discharge were recorded and analyzed using chi-square tests and t -tests ( p < 0.05 significant). Results: A total of 20 patients were enrolled (M:F = 1:2.3; 14 females, 6 males); mean age was 22.85 years (standard deviation ±8.33). Unknown etiology predominated ( n = 14, 70%); known causes included autoimmune encephalitis (NMDA-R [N-methyl-D-aspartate receptor], n = 4), neuromyelitis optica spectrum disorder (myelin oligodendrocyte glycoprotein, n = 1), and systemic lupus erythematosus-related posterior reversible encephalopathy syndrome ( n = 1). Among unknown etiology cases, 10 were cryptogenic NORSE and 4 were FIRES. FIRES patients were significantly younger than cryptogenic NORSE (11.75 vs. 27.00 years; p = 0.001). SRSE occurred in 75% of patients overall and was significantly more frequent in the unknown etiology group ( p = 0.024). All patients received first-line immunotherapy with intravenous methylprednisolone and intravenous immunoglobulin. Second-line immunotherapy was required in 55% of cases: rituximab ( n = 6, 30%), bortezomib ( n = 3, 15%), and tocilizumab ( n = 2, 10%). The mean number of ASMs used was significantly higher in the unknown etiology group (7.29 vs. 5.67; p = 0.046). Delayed first ASM (> 12 hours) strongly correlated with SRSE ( p = 0.001) and poor functional outcome ( p = 0.001). SE duration > 14 days was associated with significantly worse outcomes ( p = 0.008). Hippocampal and cortical atrophy on MRI significantly predicted medication-refractory seizures ( p = 0.018). Overall, 60% had poor functional outcomes (GOS < 4). Conclusion: Early initiation of antiseizure therapy is the single most critical determinant of outcome in NORSE/FIRES. Unknown etiology, prolonged SE, and MRI-evident hippocampal atrophy are key predictors of poor prognosis. Standardized treatment protocols, robust autoimmune workup, and timely immunotherapy are essential to improve outcomes in this rare but devastating condition. Publication History Article published online: 15 July 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Private Limited A-13A, Graphix Tower 1, 6th floor, Sector 62, Noida 201309, Uttar Pradesh, India
No takes yet. Share an insight, caveat, or question.
Phanindher et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: